GI Innovation, Inc., a bio-venture company, engages in the research and development of protein new drugs. The company is developing GI-101/GI-102, an immune anticancer drug with novel dual fusion protein in Phase I/II clinical trial; GI-108, an metabolic immunotherapy oncology agent; and GI-301, an IgE-mediated allergy treatment designed as a fusion protein that is in Phase I clinical trial. It is also developing GI-10N, an immuno-oncology drug; GI-30N, a drug for allergic and fibrotic diseases; and GI-20N, a drug for metabolic diseases. The company was founded in 2017 and is based in Seoul, South Korea.
Metrics to compare | 358570 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship358570PeersSector | |
|---|---|---|---|---|
P/E Ratio | −19.0x | −9.4x | −0.6x | |
PEG Ratio | −1.31 | −0.29 | 0.00 | |
Price/Book | 8.5x | 3.4x | 2.6x | |
Price / LTM Sales | 2,926.4x | 15.8x | 3.3x | |
Upside (Analyst Target) | - | 34.8% | 45.0% | |
Fair Value Upside | Unlock | 14.1% | 6.1% | Unlock |